Jennifer Lachey, Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 9,771 shares at $59.10 ($585K) on 2021-04-12, disclosed to the SEC on 2021-04-14.
Open-market sale of $585k KROS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $59.10 | 998 | $59K | 10.1% |
| 2 | $59.10 | 998 | $59K | 10.1% |
| 3 | $59.99 | 3,473 | $208K | 35.6% |
| 4 | $59.99 | 3,473 | $208K | 35.6% |
| 5 | $61.08 | 729 | $45K | 7.6% |
| 6 | $61.72 | 100 |
| $6K |
| 1.1% |
| Total | $59.91 avg | 9,771 | $585K | 100% |
| Filing → |
| KROS | SELL | 2022-05-13 | $362K | — | Filing → |
| KROS | SELL | 2022-04-13 | $630K | — | Filing → |
| KROS | SELL | 2022-04-06 | $477K | — | Filing → |